Investor Relations

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.
Stock Information
ENTL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 02/27/18 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: ENTL.O.  Currently trading at $24.00 with a 52 week high of $25.58 and a 52 week low of $11.47.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Financial Reconciliations
Non-GAAP Financial Measure Reconciliations - Click Here
Recent NewsMore >>
06/28/18Multi-Center Market Research Confirms Nasal Valve Collapse as a Contributor for Most Nasal Obstruction Sufferers
06/19/18Entellus Medical announces publication of the 1-year results of a randomized controlled trial comparing balloon dilation with medical therapy for treatment of persistent Eustachian tube dysfunction
05/31/18Entellus Medical Announces Multi-Center Clinical Study Publication Confirming Nasal Obstruction Symptom Improvement from LATERA
12/07/17Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $24.00 Per Share in Cash
Upcoming EventsMore >>
There are currently no events scheduled.